Hidroxizina Generis (Hydroxyzine Hydrochloride)

Hidroxizina Generis is prescribed for several therapeutic purposes related to its antihistamine and central nervous system effects.

• Relief of itching (pruritus) associated with allergic skin conditions such as urticaria or atopic dermatitis.
• Management of anxiety or tension in short‑term clinical situations.
• Adjunctive treatment for sedation before minor surgical or diagnostic procedures.
• Control of histamine‑mediated symptoms in allergic reactions, including rash or hives.
• Supportive therapy for patients with anxiety‑related insomnia when other options are unsuitable.

• Hydroxyzine hydrochloride acts primarily as a selective antagonist of peripheral H1 histamine receptors, preventing histamine‑induced vasodilation, increased vascular permeability, and sensory nerve activation that cause itching and allergic symptoms. The drug also penetrates the central nervous system, where it exerts anticholinergic activity and modulates neurotransmitter release, contributing to its sedative and anxiolytic effects. These combined actions underlie its clinical utility in pruritus and anxiety management.

Like other antihistamines, Hidroxizina Generis may cause a range of adverse reactions, most of which are mild and transient.

Common

• Drowsiness or mild sedation.
• Dry mouth, throat, or nasal passages.
• Blurred vision or difficulty focusing.
• Constipation or reduced gastrointestinal motility.
• Headache or light‑headedness.

Serious

• Significant hypotension or cardiovascular collapse.
• Severe allergic reactions such as anaphylaxis.
• Cardiac arrhythmias, especially in patients with pre‑existing heart disease.
• Marked confusion or delirium, particularly in the elderly.

Healthcare providers should evaluate individual risk factors before prescribing Hidroxizina Generis and advise patients on safe use.

• Avoid operating machinery or driving until the sedative effect is known.
• Use cautiously in patients with glaucoma, urinary retention, or enlarged prostate due to anticholinergic activity.
• Assess liver or kidney impairment, as reduced clearance may increase drug exposure.
• Monitor elderly patients closely because they are more susceptible to sedation and confusion.
• Discontinue use if signs of severe hypotension or allergic reaction appear.
• Consider alternative therapy during pregnancy or breastfeeding, as safety data are limited.

Hidroxizina Generis can interact with other medications, altering its efficacy or increasing the risk of adverse effects.

Avoid

• Concurrent use with other central nervous system depressants (e.g., benzodiazepines, opioids, alcohol) that may intensify sedation.
• Combination with monoamine oxidase inhibitors (MAOIs) or other antihistamines that can increase anticholinergic burden.

Use with caution

• Co‑administration with drugs that prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).
• Concurrent use of CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) which may raise hydroxyzine plasma levels.
• Combining with anticholinergic agents (e.g., diphenhydramine, tricyclic antidepressants) may exacerbate dry mouth and constipation.